Cellectis has 23 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile.
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with 23 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
TALEN® is a registered trademark owned by Cellectis.
Here are some of our milestones
1999: Cellectis is founded
In 2000, Institut Pasteur grants exclusive rights on 9 patent families, including several based on André Choulika’s research, genesis of the gene editing field.
2005: Breakthrough: Cellectis enables the industrial production of nucleases
Cellectis research teams provide proof of the in vivo efficacy of meganucleases, the molecular "scissors" that enable us to precisely reprogram the genome of any living organism as needed – be it human, animal, vegetable, bacterium, or virus. Gene editing is born, and with it the possibility to industrialize a once unpredictable, predominantly manual science. A tremendous leap forward for researchers, pharmaceutical laboratories, and seed producers alike.
2007: Listing on the Euronext Growth market of Euronext market of Euronext in Paris
With its impressive patent portfolio and enormous potential for growth, Cellectis makes a successful initial public offering on the Euronext Growth market of Euronext in Paris (21.2 million Euros).
2008 – 2010: Acquisition of technologies and establishment of subsidiaries
2010: Acquisition of all assets of CytoPulse Inc., based in Maryland
The acquisition included Hybrimune electrofusion technology and PulseAgile technology for RNA transfection by electroporation. PulseAgile is now the standard technology for RNA transfection of T-cells.
2010: Founding of Cellectis plant sciences, Inc. (now Calyxt, Inc.)
2011: TAL nucleases patents are exclusively licensed to Cellectis by the University of Minnesota
2014: Strategic collaboration agreement with Servier
In February, Cellectis and Servier announce collaboration in allogeneic cell therapy to develop and commercialize novel product candidates targeting leukemia and other potential tumors.
2014: Global strategic cancer immunotherapy collaboration with Pfizer
In June, Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration to develop immunotherapies against selected targets in the field of oncology.
2015: Listing on the Nasdaq Global market in New York
As the first company to create allogeneic CAR T-cells from healthy donors rather than from the patients themselves, Cellectis makes the second largest IPO in the CAR T space with a total of 228.250 million USD.
2015: First-in-man compassionate use of UCART19 for acute lymphoblastic leukemia (ALL)
In November, Cellectis announced that Great Ormond Street Hospital (GOSH) and University College London (UCL) will present encouraging data from a first in man clinical use of UCART19, at the 57th American Society of Hematology (ASH) Annual Meeting in Orlando during the poster session.
2016: Ongoing clinical trials of UCART19
Two ongoing clinical studies of UCART19 product candidate have started in June 2016. The first one is a Phase 1 pediatric study sponsored by Servier and conducted by University College London, UK in patients with acute lymphoblastic leukemia (ALL). The second one is a Phase 1 adult study sponsored by Servier and conducted by King’s College London, UK in patients with acute lymphoblastic leukemia (ALL).
2018: Global strategic collaboration agreement originally formed between Cellectis and Pfizer in 2014 is assumed by Allogene
2018: Closing of a $175 million U.S. public offering
2019: Cellectis Enters Lease Agreement to Build Manufacturing Facility, Advancing Towards Commercialization of its UCART Portfolio
2019: First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
On October 29, the Company announced that it dosed the first patient in its UCARTCS1 Phase 1 clinical trial, MELANI-01, the first allogeneic off-the-shelf CAR-T product candidate the U.S. Food and Drug Administration (FDA) has cleared to enter into clinical development for relapsed/refractory multiple myeloma (R/R MM).
2019: New IND Granted by FDA for UCART123 Following Change in Production Process and Site Initiation Ongoing for AMELI-01 Phase 1 Dose Escalation Clinical Trial for Relapsed/Refractory Acute Myeloid Leukemia
2019: 1st Patient Dosed with Cellectis' Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
On December 2, the Company announced the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate had been dosed at The University of Texas MD Anderson Cancer Center. This clinical study, BALLI-01, evaluates the safety, expansion, persistence and clinical activity of UCART22 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
2020: First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate in Relapsed/Refractory Acute Myeloid Leukemia for the AMELI-01 Clinical Trial
On January 15, Cellectis announced that the first patient had been dosed at The University of Texas MD Anderson Cancer Center in AMELI-01, a Phase 1 clinical trial that uses a new UCART123 construct with an optimized production process and new IND number from the FDA. The AMELI-01 study replaces the first US clinical trial assessing the UCART123 product candidate.